Mind Medicine (MindMed) Inc. Provided Anticipated production milestones for 2024. Generalized Anxiety Disorder (GAD): In December 2023, the Company announced statistically significant and clinically meaningful topline 4-week results from the 198- patient Phase 2b dose-optimization study of MM-120 for the treatment of GAD. MM-120 100 µg - the dose achieving the highest level of clinical activity - demonstrated a 7.6-point reduction on the Hamilton Anxiety rating scale (HAM- A) compared to placebo at Week 4 (-21.3 MM-120 vs.

-13.7 placebo; p<0.0004; Cohen's d effect size=0.88), which is more than double the effect sizes seen with the current standards of care. Clinical response (50% or greater improvement in HAM-A) at Week 4 was achieved in 78% of participants treated with MM-120 (100 µg or 200 µg) compared to 31% for placebo. Clinical remission (HAM-A 7) at Week 4 was achieved in 50% of participants treated with MM-120 100 µg. The Company plans to share topline 12-week results from the Phase 2b study by the end of the first quarter of 2024, and present full results at a scientific meeting in 2024.

The Company intends to share results in the first quarter of 2024 from its pharmacokinetics bridging study of the MM-120 Zydis® orally disintegrating tablet (ODT) formulation, its intended commercial formulation of MM-120 formulation that may enhance intellectual property and market protection with a potentially differentiated biopharmaceutical profile. The Company plans to hold an End-of-Phase 2 meeting with the FDA in the first half of 2024 and expects to initiate its Phase 3 clinical program in the second half of 2024. One-year follow-up data from a Phase 2 placebo-controlled investigator-initiated clinical trial of lysergide in the treatment of anxiety disorders is anticipated in 2024.

This study was conducted by the Company's collaborators at University Hospital Basel (UHB) in Switzerland. Attention-Deficit/Hyperactivity Disorder (ADHD): The Company's 53-patient Phase 2a proof-of-concept trial in ADHD was designed to assess the safety and efficacy of repeated sub-perceptual dose (20 g) lysergide administration and did not meet its primary endpoint. In conjunction with the findings from study of MM-120 in GAD.

The Company intends to continue prioritizing development of its MM-120 program in GAD and other psychiatric indications, using the single perceptual dose (100 g or greater) regimen that has shown strong positive results in numerous studies. MM-402 (R(-)-MDMA) for Autism Spectrum Disorder (ASD): The Company initiated its first clinical trial of MM-402 (R(-)-MDMA), a single- ascending dose study in adult healthy volunteers in Fourth Quarter 2023. This Phase 1 study is intended to characterize the tolerability, pharmacokinetics and pharmacodynamics of MM-402 and will enable further clinical studies to characterize the effects of repeated daily doses of MM402 and the exploration of early signs of efficacy in the ASD population.

In October 2023, the Company presented results from a MM-402 nonclinical study in a model of ASD, titled "MM-402 demonstrates better efficacy than S(+)-3,4-MDMA or (±)-3,4-MDMA in Fmr1 knockout mice, an animal model of autism spectrum disorder" at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress. UHB is currently conducting a Phase 1 investigator-initiated trial of R(-)-MDMA, S(+)- MDMA and R/S-MDMA in healthy adult volunteers. This trial is designed to assess the tolerability, pharmacokinetics and acute subjective, physiological and endocrine effects of the three molecules.

The Company anticipates topline results to be presented in the first half of 2024.